Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 1,625 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $79.12, for a total transaction of $128,570.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Neurocrine Biosciences, Inc. (NBIX) traded up $2.68 during trading on Thursday, reaching $78.56. 954,529 shares of the company traded hands, compared to its average volume of 1,110,858. Neurocrine Biosciences, Inc. has a 12-month low of $38.43 and a 12-month high of $83.84. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. The firm has a market cap of $6,950.00, a P/E ratio of -35.39 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same quarter last year, the business posted ($0.43) EPS. research analysts predict that Neurocrine Biosciences, Inc. will post -1.61 earnings per share for the current year.

Several analysts have recently commented on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 price target (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Citigroup reaffirmed a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Barclays lifted their price target on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, November 2nd. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Finally, BMO Capital Markets lifted their price target on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $82.31.

Several large investors have recently bought and sold shares of the business. FMR LLC grew its stake in shares of Neurocrine Biosciences by 9.8% in the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after acquiring an additional 1,180,874 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Neurocrine Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock worth $318,426,000 after acquiring an additional 186,329 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Neurocrine Biosciences by 2.6% in the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after acquiring an additional 140,639 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Neurocrine Biosciences by 33.9% in the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after acquiring an additional 1,214,000 shares in the last quarter. Finally, BB Biotech AG grew its stake in shares of Neurocrine Biosciences by 7.7% in the second quarter. BB Biotech AG now owns 3,446,552 shares of the company’s stock worth $158,541,000 after acquiring an additional 245,000 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/18/neurocrine-biosciences-inc-nbix-insider-haig-p-bozigian-sells-1625-shares.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.